Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2000-04-28
2003-12-16
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S443000, C424S444000, C424S085100, C424S085200, C424S489000, C428S370000, C435S069500, C435S069100, C435S069510
Reexamination Certificate
active
06663878
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to compositions and methods for use in the transient suppression of the inflammatory response by suppressing plasma levels of tissue necrosis factor-alpha and increasing plasma levels of interleukin-6.
BACKGROUND OF THE INVENTION
When an injury occurs, cell damage initially comes from the precipitating event, such as a cut, resulting in ruptured cells and severed or crushed capillaries and other blood vessels. The interruption of blood flow results in anoxia, causing the death of additional cells. The wound site quickly fills with dead and dying cells, extracellular substances (collagen, elastic fibers, fat and ground substances), extravasated blood, and possibly bacteria and viruses introduced during the injury.
Tissue damage is not restricted to the initial area of injury, and may increase over the next several hours or days as a result of the release of lysomal enzymes from the injured cells or as a consequence of inflammation (swelling) and/or infection. (See Reese et al., Role of Fibronectin in Wound Healing, the subject matter of which is hereby incorporated by reference.) The inflammatory response is one of the normal stages of wound healing, and is necessary for subsequent phases of healing.
Inflammation is a vital process necessary for an organism to survive an external insult, such as a wound or burn. However, if unchecked, inflammation can have harmful consequences. For example, many chronic and even life-threatening disorders, such as asthma, rheumatoid arthritis, lung fibrosis, peritoneal adhesions, hypersensitivity and autoimmune diseases are a result of an uncontrolled inflammatory response. An unresolved inflammation in the lung resulting from bacterial infection (i.e., pneumonia) may eventually lead to extensive tissue damage and a chronic lung abscess. Inflammation of the peritoneal cavity, for example, and the resulting adhesions following abdominal surgery is a major cause of infertility in women. Asthma is an often life-threatening disorder which results from an inadvertently stimulated inflammatory response in the lungs. An excessive inflammatory response can cause extensive swelling, which can lead to additional injury as a result of anoxia. Pain results from a combination of kinins and the effect of lysozymes and pressure from the swelling on nerve endings. Unchecked, the inflammatory response can set off a neural feedback loop and cause hyperalgesia, a phenomenon in which the surrounding area of injury remains painful. Accordingly, there is a great interest in the medical community to develop anti-inflammatory agents.
Many known anti-inflammatory compositions reduce the inflammatory response, but are also immunosuppressive. For example, corticosteroids are potent anti-inflammatory agents, but are associated with T-cell suppression and increased infections. Interleukin-10 (as well as IL-4 and IL-3 to lesser extents) are broadly acting anti-inflammatory agents, but are associated with decreased cell mediated immune functions.
It would be advantageous to provide compositions and methods which provide protection from adverse effects associated with inflammation, preferably without unnecessary immunosuppression. The present invention provides such compositions and methods.
SUMMARY OF THE INVENTION
Compositions and methods for providing protection from adverse effects associated with inflammation are disclosed. The compositions and methods can suppress plasma concentrations of tissue necrosis factor-alpha (TNF-&agr;) while increasing plasma concentrations of interleukin-6 (IL-6).
The compositions include non-interlinked particles of bioactive glass with a size less than about 20 &mgr;m, alone or in combination with an additional anti-inflammatory agent, and optionally include other therapeutic agents. Formulations including the composition and a suitable carrier, preferably for oral, intramuscular, intraperitoneal or intravenous administration, are also disclosed.
The composition can be administered orally, intramuscularly, intraperitoneally or intraveneously to provide systemic relief from the adverse effects associated with inflammation, for example, the effects of excess TNF-&agr;.
REFERENCES:
patent: 4103002 (1978-07-01), Hench et al.
patent: 4272518 (1981-06-01), Moro et al.
patent: 4303066 (1981-12-01), D'Andrea
patent: 4538603 (1985-09-01), Pawelchak et al.
patent: 4539200 (1985-09-01), Quarfoot
patent: 4599209 (1986-07-01), Dautzenberg et al.
patent: 4605415 (1986-08-01), Richez
patent: 4613502 (1986-09-01), Turkova et al.
patent: 4788642 (1988-11-01), Suzuki et al.
patent: 4837285 (1989-06-01), Berg et al.
patent: 4851046 (1989-07-01), Low et al.
patent: 5000746 (1991-03-01), Meiss
patent: 5017627 (1991-05-01), Bonfield et al.
patent: 5068122 (1991-11-01), Kokubo et al.
patent: 5126141 (1992-06-01), Henry
patent: 5236458 (1993-08-01), Ducheyne et al.
patent: 5263992 (1993-11-01), Guire
patent: 5290544 (1994-03-01), Shimono et al.
patent: 5298260 (1994-03-01), Viegas et al.
patent: 5340776 (1994-08-01), Paschke et al.
patent: 5352715 (1994-10-01), Wallace et al.
patent: 5410016 (1995-04-01), Hubbell et al.
patent: 5501706 (1996-03-01), Arenberg
patent: 5536614 (1996-07-01), Kondo et al.
patent: 5591453 (1997-01-01), Ducheyne et al.
patent: 5648301 (1997-07-01), Ducheyne et al.
patent: 5681575 (1997-10-01), Burrell et al.
patent: 5681872 (1997-10-01), Erbe
patent: 5696169 (1997-12-01), Otsu et al.
patent: 5707829 (1998-01-01), Jacobs et al.
patent: 5728753 (1998-03-01), Bonfield et al.
patent: 5753251 (1998-05-01), Burrell et al.
patent: 5766611 (1998-06-01), Shimono et al.
patent: 5807641 (1998-09-01), Oku et al.
patent: 5834008 (1998-11-01), Greenspan et al.
patent: 5840290 (1998-11-01), Hench et al.
patent: 5990380 (1999-11-01), Marotta et al.
patent: 6083521 (2000-07-01), Acemoglu et al.
patent: 6086374 (2000-07-01), Litkowski et al.
patent: 97/17401 (1994-03-01), None
patent: 98/11853 (1998-03-01), None
patent: 99/13582 (1999-03-01), None
patent: 00/66086 (2000-11-01), None
“Interaction of bioactive glasses with peritneal macrophages and minocytes in vitro”, Bosetti et al, Journal of Biochemical Materials Research, 60 (1), pp. 79-85.*
Aydin, M., et al., “Deposition Profile of Antibacterial Anodic Silver in Root Canal Systems of Teeth”,J. Biomed. Mater. Res., 38(1):49-54, (John Wiley & Sons, Inc.) 1997).
Barrett, E. P., et al., “The Determination of Pore Volume and Area Distributions in Porous Substances. I. Computations from Nitrogen Isotherms”,J. Am. Chem. Soc., 73:373-380 (American Chemical Society) 1951.
Bergna, H.E., “The Colloid Chemistry of Silica”,Advances in Chemistry, Series 234 (American Chemical Society, Washington, DC) 1994.
Bosetti, M., et al., “Effects of Bioactive Glass on Macrophages Activation”,Bioceramics, 11: 319-322, (Word Scientific Pub. Co.) 1998.
Brinker, C. J., et al., “The Physics and Chemistry of Sol-Gel Processing”,Sol-Gel Science, 8: 499-503 (Academic Press, Inc.) 1990.
Brinker, C. J., et al., “The Physics and Chemistry of Sol-Gel Processing”,Sol-Gel Science, 3: 115-119 (Academic Press, Inc.) 1990.
Carlisle, E. M., “Silicon Biochemistry, Silicon as an Essential Trace Element in Animal Nutrition”,Ciba Foundation Symposium 121, 123-139 (John Wiley and Sons, New York) 1986.
Cartmell, S. H., et al., “Soft Tissue Response to Glycerol-suspended Controlled-release Glass Particulate”,J. Mat. Science: Mat. in Med., 9: 773-777 (Kluwer Academic Publishers) 1998.
Coleman, J. J., et al., “Mandibular Reconstruction with Composite Microvascular Tissue Transfer”,Medicine, (Abstract) #91023289, 1991.
Freed, J. S., “Use of Injectable Biomaterials for the Repair and Augmentation of the Anal Sphincter”,Chemical Abstract, 119:#195701, 1993.
Fung, M. C. et al., “Silver Products for Medical Indications: Risk-Benefit Assessment”,J. Toxicol., 34(1):119-126 (American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologist) 1996.
Goldman Sachs/U.S. Research, “Advanced Tissue Sciences, (ATS)”, (Healthcare: Biotechnology)1-30, 1996.
Gr
Greenspan David C.
Lee Sean
Walpole Marlo tan
Page Thurman K.
Pulliam Amy E
USBIOMATERIALS Corp.
LandOfFree
Anti-inflammatory bioactive glass particulates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-inflammatory bioactive glass particulates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory bioactive glass particulates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3181007